PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for ...
Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its ...
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported its second-quarter 2025 results, showcasing clinical progress in gene therapy, new strategic partnerships, and a planned spin-off to sharpen its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback